Tuesday, 10 February 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 10 February 2026
News

Companies request PBAC rethink

Posted 10 February 2026 AM 

As the PBAC March meeting rolls closer it has updated the agenda again, with sponsors asking the Committee to look at the requirements for prescribing their treatments.

Arrotex now has a submission for the PBAC to review the revised proposed price, the restrictions, and the previously estimated utilisation of aZematop in treating atopic dermatitis from its July 2025 recommendation.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (12)

Access & Reimbursement (1)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (4)

Other (19)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.